Latest G protein-coupled receptor Stories
SEATTLE, May 22, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the following two conferences: 38(th) Annual Deutsche Bank dbAccess Health Care ConferenceMay 29, 20132:10 p.m. EDTBoston, MA...
SEATTLE, May 14, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported that it closed the registered direct offering of 3,903,004 shares of its common stock that was announced on May 9, 2013. The shares were sold at a price of $4.14 per share, which represented a two percent premium over the closing price on May 8, 2013. The shares were sold directly to affiliates of RA Capital Management and other investors without an underwriter or placement agent. Omeros...
SEATTLE, May 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the first quarter of 2013. Financial Results Total operating expenses for the quarter ended March 31, 2013 were $11.1 million compared to $9.6 million for the same period in...
Forest Laboratories leads Trevena's $60 Million Series C Funding Round; All existing investors to also participate KING OF PRUSSIA, Pa. and NEW YORK, May 9, 2013 /PRNewswire/ -- Trevena, Inc., (Trevena) a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, and Forest Laboratories Holding Limited (Forest), a subsidiary of Forest Laboratories Inc. (NYSE: FRX), an international pharmaceutical company,...
WELWYN GARDEN CITY, England and BOSTON, April 29, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery and development company, announces it has achieved all milestones in its collaboration with Takeda Pharmaceutical Company. By achieving these milestones, Heptares will receive a significant payment from Takeda, under the terms of the agreement signed by the two companies in 2011. The agreement is focused on a single GPCR target nominated by...
SEATTLE, April 24, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it will present at the 12(th) Annual Needham Healthcare Conference next week. Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at 8:40 a.m. Eastern Time on Wednesday, May 1,...
A three-dimensional image of one of the proteins that serves as an on-off switch as it binds to receptors on the surface of a cell suggests there may be a sort of main power switch that could be tripped. These surface receptors are responsible for helping cells discern light, set the heart racing, or detect pain. The finding, published online April 21, 2013, in the journal Nature by a research collaboration involving this year's Nobel laureates in chemistry, could help in the development...
WELWYN GARDEN CITY, England and BOSTON, April 16, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, notes that it will be presenting at the following scientific conferences and biotech industry events over the coming weeks. 8th Annual Drug Discovery Chemistry [http://www.drugdiscoverychemistry.com/GPCR-Drug-Design ] (San Diego, CA, USA, April 16-18) Dr Rob Cooke, Heptares' Head of Biomolecular Structure, will give a...
- Adds to Earlier Data Demonstrating Potential to Restore Myelin in MS Patients - SEATTLE, April 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled...
WELWYN GARDEN CITY, England and BOSTON, April 2, 2013 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR drug discovery company, notes that Dan Grau (Heptares' President) will attend the Boston Biotech BD Conference [http://bbbiotechconference.com/conference-agenda.php?id=10 ] taking place at the Four Seasons Hotel, Boston, MA, USA (2-3 April), at which he will participate in a panel discussion entitled Listening to Patients While Setting Company Goals: More Important...
